Skip to main content

Table 2 Percent proliferation inhibition by Treg at different Treg:Th ratios at either baseline or 6 week timepoints

From: Phenotypic and functional testing of circulating regulatory T cells in advanced melanoma patients treated with neoadjuvant ipilimumab

  1. aTimepoint; bTreg:Th ratio; cPatient number; dResults highlighted in blue represent a decrease in percent of maximal inhibition post-ipi compared to corresponding baseline sample